Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 1.56% | |
| Lower Bollinger Band Walk | Weakness | 1.56% | |
| Inside Day | Range Contraction | 1.56% | |
| Down 3 Days in a Row | Weakness | 1.56% | |
| Down 4 Days in a Row | Weakness | 1.56% | |
| Lower Bollinger Band Touch | Weakness | 1.56% | |
| Oversold Stochastic | Weakness | 1.56% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 8 hours ago |
| Up 1 ATR | about 9 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Up 3% | about 10 hours ago |
| Up 2% | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 07/31/2024
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibodies Monoclonal Antibody Lymphoma Oncogenes Protein Kinase Bruton's Tyrosine Kinase Ras Subfamily Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 225.23 |
| 52 Week Low | 126.9681 |
| Average Volume | 191,239 |
| 200-Day Moving Average | 166.97 |
| 50-Day Moving Average | 156.27 |
| 20-Day Moving Average | 155.08 |
| 10-Day Moving Average | 151.55 |
| Average True Range | 6.09 |
| RSI (14) | 39.02 |
| ADX | 14.96 |
| +DI | 22.54 |
| -DI | 30.79 |
| Chandelier Exit (Long, 3 ATRs) | 150.90 |
| Chandelier Exit (Short, 3 ATRs) | 159.58 |
| Upper Bollinger Bands | 168.82 |
| Lower Bollinger Band | 141.33 |
| Percent B (%b) | 0.13 |
| BandWidth | 17.73 |
| MACD Line | -3.12 |
| MACD Signal Line | -1.35 |
| MACD Histogram | -1.7682 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 153.20 | ||||
| Resistance 3 (R3) | 153.63 | 151.28 | 151.82 | ||
| Resistance 2 (R2) | 151.28 | 149.17 | 151.07 | 151.35 | |
| Resistance 1 (R1) | 148.09 | 147.86 | 149.69 | 147.66 | 150.89 |
| Pivot Point | 145.74 | 145.74 | 146.54 | 145.53 | 145.74 |
| Support 1 (S1) | 142.55 | 143.63 | 144.15 | 142.12 | 138.89 |
| Support 2 (S2) | 140.20 | 142.32 | 139.99 | 138.43 | |
| Support 3 (S3) | 137.01 | 140.20 | 137.97 | ||
| Support 4 (S4) | 136.58 |
